1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Therapeutic Neurotoxin Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Therapeutic Neurotoxin Market Revenue and Volume, by Neurotoxin Type
8.1.1 Botulinum toxin type A 
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Botulinum toxin type B
8.1.2.1. Market Revenue and Volume Forecast
9.1. Therapeutic Neurotoxin Market Revenue and Volume, by End User
9.1.1. Hospitals
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Specialty neurology clinics
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Rehabilitation centers
9.1.3.1. Market Revenue and Volume Forecast
10.1. Therapeutic Neurotoxin Market Revenue and Volume, by Route of Administration
10.1.1. Intramuscular
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Intradermal
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Intravesical
10.1.3.1. Market Revenue and Volume Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Neurotoxin Type
11.1.2. Market Revenue and Volume Forecast, by End User
11.1.3. Market Revenue and Volume Forecast, by Route of Administration
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Neurotoxin Type
11.1.4.2. Market Revenue and Volume Forecast, by End User
11.1.4.3. Market Revenue and Volume Forecast, by Route of Administration
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Neurotoxin Type
11.1.5.2. Market Revenue and Volume Forecast, by End User
11.1.5.3. Market Revenue and Volume Forecast, by Route of Administration
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Neurotoxin Type
11.2.2. Market Revenue and Volume Forecast, by End User
11.2.3. Market Revenue and Volume Forecast, by Route of Administration
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Neurotoxin Type
11.2.4.2. Market Revenue and Volume Forecast, by End User
11.2.4.3. Market Revenue and Volume Forecast, by Route of Administration
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Neurotoxin Type
11.2.5.2. Market Revenue and Volume Forecast, by End User
11.2.5.3. Market Revenue and Volume Forecast, by Route of Administration
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Neurotoxin Type
11.2.6.2. Market Revenue and Volume Forecast, by End User
11.2.6.3. Market Revenue and Volume Forecast, by Route of Administration
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Neurotoxin Type
11.2.7.2. Market Revenue and Volume Forecast, by End User
11.2.7.3. Market Revenue and Volume Forecast, by Route of Administration
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Neurotoxin Type
11.3.2. Market Revenue and Volume Forecast, by End User
11.3.3. Market Revenue and Volume Forecast, by Route of Administration
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Neurotoxin Type
11.3.4.2. Market Revenue and Volume Forecast, by End User
11.3.4.3. Market Revenue and Volume Forecast, by Route of Administration
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Neurotoxin Type
11.3.5.2. Market Revenue and Volume Forecast, by End User
11.3.5.3. Market Revenue and Volume Forecast, by Route of Administration
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Neurotoxin Type
11.3.6.2. Market Revenue and Volume Forecast, by End User
11.3.6.3. Market Revenue and Volume Forecast, by Route of Administration
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Neurotoxin Type
11.3.7.2. Market Revenue and Volume Forecast, by End User
11.3.7.3. Market Revenue and Volume Forecast, by Route of Administration
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Neurotoxin Type
11.4.2. Market Revenue and Volume Forecast, by End User
11.4.3. Market Revenue and Volume Forecast, by Route of Administration
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Neurotoxin Type
11.4.4.2. Market Revenue and Volume Forecast, by End User
11.4.4.3. Market Revenue and Volume Forecast, by Route of Administration
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Neurotoxin Type
11.4.5.2. Market Revenue and Volume Forecast, by End User
11.4.5.3. Market Revenue and Volume Forecast, by Route of Administration
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Neurotoxin Type
11.4.6.2. Market Revenue and Volume Forecast, by End User
11.4.6.3. Market Revenue and Volume Forecast, by Route of Administration
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Neurotoxin Type
11.4.7.2. Market Revenue and Volume Forecast, by End User
11.4.7.3. Market Revenue and Volume Forecast, by Route of Administration
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Neurotoxin Type
11.5.2. Market Revenue and Volume Forecast, by End User
11.5.3. Market Revenue and Volume Forecast, by Route of Administration
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Neurotoxin Type
11.5.4.2. Market Revenue and Volume Forecast, by End User
11.5.4.3. Market Revenue and Volume Forecast, by Route of Administration
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Neurotoxin Type
11.5.5.2. Market Revenue and Volume Forecast, by End User
11.5.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.1. AbbVie/Allergan
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Ipsen
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Merz Therapeutics
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Revance Therapeutics
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Galderma S.A.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Hugel
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Daewoong Pharmaceutical
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Medytox
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Evolus
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Lanzhou Institute of Biological Products
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
